Combination of GT103 with pembrolizumab was well tolerated with no new safety signals. A subset of patients experienced durable responses and disease control despite prior exposure to ICI.
Jeffrey Clarke, Thomas E. Stinchcombe, Jeffrey Crawford, Hirva Mamdani, Lin Gu, Neal Ready, Andrew B. Nixon, Stephen Baleviic, Michael J. Campa, Liz Gottlin, Ryan T. Bushey, James E. Herndon, Scott Antonia, Edward F. Patz, George R. Simon
Jeffrey Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen J. Balevic, Andrew B. Nixon, Michael J. Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You‐Wen He, Scott Antonia, Edward F. Patz
Hirva Mamdani, Jeffrey Clarke, Lin Gu, Tom Stinchcombe, Jeffrey Crawford, Scott Antonia, Michael J. Campa, Andrew B. Nixon, Guru Sonpavde, George R. Simon, Neal Ready, James E Herndon, Edward F. Patz
David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip Pravin Patel, Aiwu Ruth He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch,
Discussion(0)
No comments yet. Be the first to comment.